Stockreport

New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications

DarioHealth Corp.  (DRIO) 
NASDAQ:AMEX Investor Relations: dariohealth.com/our-story
PDF Study presented at ATTD 2024 is the first of a planned series examining the impact of Dario's integrated cardiometabolic solution as a means to address weight and diabet [Read more]